Merck

Last updated January 31, 2026

124

Innovation Areas

5,362

Inventors

Collaborations

Small molecule cetp and pcsk9 inhibitors: MerckRecent Research Landscape

Elevated LDL cholesterol levels drive cardiovascular risk and healthcare costs. These molecular structures inhibit PCSK9 activity to restore hepatic LDL receptor density and lower circulating cholesterol.

What technical problems is Merck addressing in Small molecule cetp and pcsk9 inhibitors?

Excessive plasma cholesterol levels

(7)evidences

Elevated LDL cholesterol levels lead to atherosclerotic cardiovascular disease. Reducing circulating PCSK9 activity prevents the degradation of LDL receptors to improve lipid clearance.